Neurion was founded in 2002. The company is based on pioneering, interdisciplinary research in chemistry and molecular neurobiology performed at the California Institute of Technology by its founding scientists, Dennis A. Dougherty, Ph.D., the George Grant Hoag Professor of Chemistry, and Henry A. Lester, Ph.D., the Bren Professor of Biology.
Neurion Pharmaceuticals, Inc. is a drug discovery company with a unique technology platform for developing safer and more effective drugs that target ion channels.
Neurion Pharmaceuticals has a novel and better approach to developing and optimizing ion channel drugs. Neurion’s Precision Neurochemistry Platform (also called "NP2"), together with its proprietary ion channel Mutant Activity Panel (or MAP™) technology, enable Neurion and its partners to discover and develop drugs that have greater selectivity for specific ion channel subtypes, based upon a more precise understanding of ion channel structure and function.
Contact Information
- Address: 180 N. Vinedo Ave., Pasadena, CA 91107, USA
- Telephone number: (626) 583-5020
- Fax number: (626) 395-0683
- Web page: www.neurionpharma.com